

NOTICE REQUIRED UNDER ASX LISTING RULE 3.13.1

Melbourne, Australia, 11 October 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**), advises that the Annual General Meeting is currently scheduled for 29 November 2021. The closing date for the receipt of nominations from persons wishing to be considered for election as a director of the Company is 18 October 2021. Any nominations must be received in writing no later than 5.00pm (AEDT) on 18 October 2021 at the Company's registered office.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting which will be provided in due course.

Authorised for release by Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS:

Dr Learne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

Dr Geoff Cumming
Non-Executive Chairman
E geoff.cumming@bard1.com
M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is an Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. BARD1 has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com and www.exo-net.com.